Lucid Diagnostics Crescita futura
Criteri Future verificati 2/6
Si prevede che Lucid Diagnostics aumenterà gli utili e i ricavi rispettivamente del 12.6% e 37.9% all'anno, mentre si prevede che l'EPS crescerà del 36.1% all'anno.
Informazioni chiave
12.6%
Tasso di crescita degli utili
36.09%
Tasso di crescita dell'EPS
| Medical Equipment crescita degli utili | 16.2% |
| Tasso di crescita dei ricavi | 37.9% |
| Rendimento futuro del capitale proprio | n/a |
| Copertura analitica | Low |
| Ultimo aggiornamento | 15 May 2026 |
Aggiornamenti recenti sulla crescita futura
Recent updates
Aggiornamento della narrazione • Apr 25
LUCD: Higher Future P/E Assumptions Will Support Upside Despite Execution Risks
Analysts have lifted their price target on Lucid Diagnostics by $0.75, citing updated assumptions around the discount rate, revenue growth, profit margins, and a higher future P/E multiple as the key drivers of the change. Analyst Commentary While the higher price target reflects updated modeling assumptions, bearish analysts still flag several areas of concern that readers should keep in mind when thinking about Lucid Diagnostics.
Aggiornamento della narrazione • Apr 11
LUCD: Revised Outlook Suggests VA Contract Will Support Future Repricing
Analysts have adjusted their price target on Lucid Diagnostics from $8.25 to $9.00, reflecting updated assumptions on revenue growth, profitability, discount rate, and future P/E expectations. Analyst Commentary Recent research highlights a constructive tone around Lucid Diagnostics, with bullish analysts pointing to updated assumptions on revenue growth, profitability, discount rate, and future P/E expectations as key reasons behind the higher price target of US$9.00.
Nuova narrazione • Apr 01
Poised for success
Lucid Diagnostics' EsoGuard is a novel screening tool for esophageal cancer. It is relatively non-invasive and may become widely accepted soon.Aggiornamento della narrazione • Mar 27
LUCD: VA Contract Will Drive Broader Future Adoption And Repricing
Analysts have raised their price target for Lucid Diagnostics to $8.25. This reflects updated views on fair value, discount rate, revenue growth, profit margin, and a very high anticipated future P/E multiple.Aggiornamento della narrazione • Mar 12
LUCD: VA Contract Will Expand Screening Access And Support Future Upside
Analysts have modestly adjusted their price target for Lucid Diagnostics to reflect slightly updated assumptions on discount rate, revenue growth, profit margin, and future P/E, while keeping their overall fair value estimate steady at $2.50. What's in the News Lucid Diagnostics received a contract from the U.S. Department of Veterans Affairs for its EsoGuard Esophageal DNA Test, aimed at expanding access to esophageal precancer testing across the VA healthcare system, which serves more than 9,000,000 enrolled veterans annually (Key Developments).Aggiornamento della narrazione • Feb 26
LUCD: VA Screening Access And Safety Data Will Support Future Upside
Analysts kept their Lucid Diagnostics price target steady at $2.50, pointing to largely unchanged fair value and P/E assumptions, with only small tweaks to the discount rate, revenue growth, and profit margin inputs behind their models. What's in the News Lucid Diagnostics secured a U.S. Department of Veterans Affairs contract for its EsoGuard Esophageal DNA Test, making the test available across the VA's national integrated healthcare system that serves more than 9 million enrolled veterans each year (Key Developments).Aggiornamento della narrazione • Feb 11
LUCD: VA Screening Contract And Real World Data Will Support Future Upside
Analysts have modestly revised their price target on Lucid Diagnostics, citing adjusted assumptions for the discount rate, revenue growth, profit margin, and future P/E that maintain a fair value estimate of $2.50. What's in the News Lucid Diagnostics secured a U.S. Department of Veterans Affairs contract for its EsoGuard Esophageal DNA Test, giving VA hospitals and facilities nationwide a single procurement framework and expanding access across the system that serves more than nine million enrolled veterans annually (Key Developments).Aggiornamento della narrazione • Jan 27
LUCD: VA Contract And Real World Screening Data Will Support Future Upside
Analysts have adjusted their price target for Lucid Diagnostics slightly, maintaining fair value at about US$2.50 while fine tuning assumptions on the discount rate, revenue growth, profit margins and future P/E to reflect updated views on the company’s risk profile and earnings power. What's in the News Lucid Diagnostics secured a contract with the U.S. Department of Veterans Affairs for its EsoGuard Esophageal DNA Test, expanding access to esophageal precancer testing across the VA system, which serves more than 9,000,000 enrolled veterans annually (Key Developments).Seeking Alpha • Jan 26
Lucid Diagnostics: Green Flags, But Dilution And Friction Keep Me Neutral
Summary Lucid offers an office-based esophageal precancer screening. The FDA cleared EsoCheck sampling plus EsoGuard NGS epigenetic assay to triage EGD referrals. In my view, their core upside hinges on broader Medicare coverage. The recent CAC support and 45-day notice suggest improving odds on this front. LUCD’s Q3 2025 showed 2,841 tests and $7.1 million in pro-forma revenues billed. But, only $1.2 million could be conservatively recognized. So, there’s still considerable friction for LUCD’s underlying business. Fortunately, real-world evidence looks promising, and the VA FSS contract is a green flag. I think LUCD is heading in the right direction. But it still sports a premium valuation despite its several uncertainties and dilution risks. So I remain neutral on the stock. Read the full article on Seeking AlphaAggiornamento della narrazione • Jan 13
LUCD: Real World Screening Data Will Support Stronger Long-Term Profit Potential
Analysts have slightly reduced their price target on Lucid Diagnostics, citing updated assumptions that keep fair value steady at $2.50 while reflecting small adjustments to the discount rate, revenue growth, profit margin and future P/E expectations. What's in the News New real world data on Lucid Diagnostics EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device cover 11,991 at risk patients over 18 months of routine clinical use between January 2023 and June 2024 (medRxiv preprint).Aggiornamento della narrazione • Dec 14
LUCD: New Screening Data Will Support Stronger Long-Term Profit Potential
Analysts have raised their price target on Lucid Diagnostics by approximately 25 percent to reflect higher projected revenue growth, slightly improved long term profitability, and a modestly higher valuation multiple despite a small uptick in the assumed discount rate. What's in the News Reported new 18-month real-world data in 11,991 at-risk patients using EsoGuard and EsoCheck for nonendoscopic Barrett's esophagus screening, supporting their utility as scalable, noninvasive tools in routine clinical practice (company announcement) Study authors highlighted excellent safety and tolerability, with EsoCheck achieving a 95% technical success rate, most procedures completed in under two minutes, and no serious adverse events (company announcement) Most patients in the analysis met U.S. gastroenterology society guideline criteria for Barrett's esophagus screening, indicating appropriate physician adoption of EsoGuard and EsoCheck (company announcement) Valuation Changes Fair Value: risen moderately from 2.0x to 2.5x, reflecting a higher implied valuation multiple on forward fundamentals.Articolo di analisi • Dec 13
Is Lucid Diagnostics (NASDAQ:LUCD) Using Too Much Debt?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Nuova narrazione • Apr 12
Expanded Reimbursement And Cash-Pay Programs Will Open Future Markets
Expanding reimbursement coverage and leveraging NCCN guidelines are strategies expected to enhance revenue and credibility with payers.Articolo di analisi • May 09
We're A Little Worried About Lucid Diagnostics' (NASDAQ:LUCD) Cash Burn Rate
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Articolo di analisi • Dec 15
Lucid Diagnostics (NASDAQ:LUCD) Will Have To Spend Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Seeking Alpha • Aug 11
Lucid Diagnostics launches stage II lucid test center in California, Texas, Florida, and Ohio
Lucid Diagnostics (NASDAQ:LUCD) announced on Thursday that its subsidiary, LucidDx Labs, has launched four new Lucid Test Centers in California, Texas, Florida and Ohio. Patients in the metropolitan areas with chronic heartburn can order from their own physician or from a telemedicine physician and can now undergo a brief, non-invasive, office-based test to detect esophageal precancer before it progresses to deadly esophageal cancer, using Lucid’s EsoGuard DNA Esophageal Test. The test centers are staffed with Lucid-employed nurse practitioners who use EsoCheck to collect surface esophageal cells which are sent to LucidDx Labs for EsoGuard testing. (LUCD) has risen ~2% premarket.Articolo di analisi • Jul 07
We're Keeping An Eye On Lucid Diagnostics' (NASDAQ:LUCD) Cash Burn Rate
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Previsioni di crescita degli utili e dei ricavi
| Data | Ricavi | Utili | Flusso di cassa libero | Liquidità dell'operazione | Avg. Numero di analisti |
|---|---|---|---|---|---|
| 12/31/2028 | 29 | -43 | -33 | -28 | 2 |
| 12/31/2027 | 20 | -42 | -40 | -36 | 5 |
| 12/31/2026 | 7 | -56 | -42 | -40 | 5 |
| 3/31/2026 | 5 | -58 | -46 | -46 | N/A |
| 12/31/2025 | 5 | -71 | -47 | -46 | N/A |
| 9/30/2025 | 4 | -66 | -44 | -44 | N/A |
| 6/30/2025 | 4 | -68 | -44 | -43 | N/A |
| 3/31/2025 | 4 | -71 | -45 | -44 | N/A |
| 12/31/2024 | 4 | -53 | -45 | -44 | N/A |
| 9/30/2024 | 4 | -52 | -45 | -44 | N/A |
| 6/30/2024 | 4 | -54 | -43 | -43 | N/A |
| 3/31/2024 | 3 | -55 | -39 | -38 | N/A |
| 12/31/2023 | 2 | -53 | -33 | -33 | N/A |
| 9/30/2023 | 2 | -57 | -27 | -27 | N/A |
| 6/30/2023 | 1 | -57 | -25 | -25 | N/A |
| 3/31/2023 | 1 | -60 | -32 | -31 | N/A |
| 12/31/2022 | 0 | -56 | -31 | -30 | N/A |
| 9/30/2022 | 1 | -53 | -37 | -35 | N/A |
| 6/30/2022 | 1 | -45 | -32 | -31 | N/A |
| 3/31/2022 | 1 | -37 | -21 | -20 | N/A |
| 12/31/2021 | 1 | -28 | -19 | -18 | N/A |
| 9/30/2021 | 0 | -20 | -10 | -9 | N/A |
| 6/30/2021 | N/A | -15 | -9 | -9 | N/A |
| 3/31/2021 | N/A | -10 | -8 | -8 | N/A |
| 12/31/2020 | N/A | -8 | -6 | -6 | N/A |
| 9/30/2020 | N/A | -7 | -4 | -4 | N/A |
| 12/31/2019 | N/A | -4 | N/A | -2 | N/A |
| 9/30/2019 | N/A | -4 | N/A | -2 | N/A |
Previsioni di crescita futura degli analisti
Guadagni vs tasso di risparmio: Si prevede che LUCD rimarrà non redditizia nei prossimi 3 anni.
Guadagni vs Mercato: Si prevede che LUCD rimarrà non redditizia nei prossimi 3 anni.
Guadagni ad alta crescita: Si prevede che LUCD rimarrà non redditizia nei prossimi 3 anni.
Ricavi vs Mercato: Si prevede che il fatturato di LUCD ( 37.9% all'anno) crescerà più rapidamente del mercato US ( 11.9% all'anno).
Ricavi ad alta crescita: Si prevede che il fatturato di LUCD ( 37.9% all'anno) crescerà più rapidamente di 20% all'anno.
Previsioni di crescita dell'utile per azione
Rendimento futuro del capitale proprio
ROE futuro: Dati insufficienti per determinare se il Return on Equity di LUCD è previsto essere elevato tra 3 anni
Scoprire le aziende in crescita
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/05/31 10:04 |
| Prezzo dell'azione a fine giornata | 2026/05/29 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Lucid Diagnostics Inc. è coperta da 5 analisti. 5 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Edward Woo | Ascendiant Capital Markets LLC |
| Mark Massaro | BTIG |
| Kyle Mikson | Canaccord Genuity |